"Official medicines" is the best online drugstore.

World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system.

The meds you need, reliable and hassle free! Top products of top brands.

The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe!

(ESS-troe-PIH-pate)
Ogen, Ortho-Est
Class: Estrogen

 Action Promotes growth and development of female reproductive system and secondary sex characteristics; affects release of ovulation and prevents postpartum breast engorgement; conserves calcium and phosphorous and encourages bone formation; overrides stimulatory effects of testosterone.

 Indications Management of moderate to severe vasomotor symptoms associated with menopause; female hypogonadism, female castration, primary ovarian failure and atrophic conditions caused by deficient endogenous estrogen production; prevention and treatment of osteoporosis.

 Contraindications Breast cancer; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; thrombophlebitis or thromboembolic disorders associated with previous estrogen use; known or suspected pregnancy.

 Route/Dosage

Vasomotor Symptoms

ADULTS: PO 0.625 to 5 mg/day given cyclically.

Female Hypogonadism, Female Castration, Primary Ovarian Failure

ADULTS: PO 1.25 to 7.5 mg/day for 3 wk followed by 8 to 10 day drug-free period.

Osteoporosis

ADULTS: PO 0.625 mg/day for 25 days of 31-day cycle.

Atrophic Vaginitis, Kraurosis Vulvae

ADULTS: PO 0.625 to 5 mg/day. Give cyclically. Intravaginal 2 to 4 g daily. Give cyclically.

 Interactions

Antidepressants, tricyclic: Estrogens may alter effects and increase toxicity of these agents. Barbiturates, rifampin: May decrease estropipate concentration. Corticosteroids: An increase in the pharmacologic and toxicologic effects of corticosteroids may occur. Hydantoins: Loss of seizure control or decreased estrogenic effects may occur.

 Lab Test Interferences Endocrine and liver function test results may be affected; possible decreased PT and increased platelet aggregability; increased thyroid-binding globulin and total T4; impaired glucose tolerance; decreased serum folate concentration; increased serum triglyceride and phospholipid concentrations; increased corticosteoid binding globulin and sex-hormone binding globulin; increased plasma HDL concentrations; reduced LDL cholesterol concentrations; increased triglyceride levels.

 Adverse Reactions

CV: Thrombosis; thrombophlebitis; increased BP; pulmonary embolism; MI. CNS: Headache; migraine; dizziness; depression; insomnia; anxiety; emotional lability. DERM: Chloasma; melasma; erythema nodosum/multiforme; scalp hair loss; hirsutism; urticaria; dermatitis; skin hypertrophy; pruritus. EENT: Intolerance to contact lenses. GI: Nausea; vomiting; abdominal cramps; bloating; colitis; acute pancreatitis; diarrhea; dyspepsia; flatulence; gastritis; gastroenteritis; enlarged abdomen; hemorrhoids. GU: Increased risk of endometrial carcinoma; breakthrough bleeding; dysmenorrhea; amenorrhea; vaginal candidiasis; premenstrual-like syndrome; increased size of uterine fibromyomata; hemolytic uremic syndrome; urinary tract infection; vaginitis; vaginal discomfort/pain; cystitis; dysuria; genital pruritus; urinary incontinence. HEPA: Cholestatic jaundice. META: Hyperglycemia; hypercalcemia. RESP: Upper respiratory tract infection; sinusitis; rhinitis; pharyngitis; flu-like symptoms; allergy; bronchitis; chest pain. OTHER: Increase or decrease in weight; edema; changes in libido; breast tenderness; acute intermittent porphyria; vaginal bleeding; hypersensitivity reactions; back pain; arthritis; arthralgia; hot flushes; otitis media; toothache.

 Precautions

Pregnancy: Category X. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Calcium and phosphorus metabolism: Use drug with caution in patients with metabolic bone diseases. Fluid retention: Use drug with careful observation when conditions that might be affected by this factor are present (eg, asthma, cardiac or renal dysfunction, epilepsy). Gallbladder disease: Risk of gallbladder disease may increase in women receiving postmenopausal estrogens. Hepatic function impairment: Metabolism may be impaired; use drug with caution. Induction of malignant neoplasms: May increase risk of endometrial or other carcinomas. Familial hyperlipoproteinemia: May be associated with massive elevations of plasma triglycerides. Uterine leiomyomata: Preexisting uterine leiomyomata may increase in size. Unopposed estrogen administration (eg, without progesterone): Increases risk of uterine cancer. Therefore, when using estrogens on long-term basis in a woman with intact uterus, consider cyclic therapy with progesterone (eg, estrogen on days 1 to 25 of mo with progesterone added for last 12 days) or daily coadministration of estrogen plus progesterone on daily basis. In a woman without uterus, use of cyclic therapy and/or therapy with progesterone is not necessary.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

  • Administer vaginal cream high in vagina (about  length of applicator).
  • Give tablets with meal to decrease GI upset.

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Include in physical assessments BP measurements, and examination of breasts, abdomen and pelvic organs. Review results of Pap test, which should be conducted at least annually.
  • Monitor blood sugar in diabetic patients and report changes to health care provider.
  • Be alert for changes in liver function test results and possible decreased PT.
OVERDOSAGE: SIGNS & SYMPTOMS
  Nausea, withdrawal bleeding in women

 Patient/Family Education

  • Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use reliable form of birth control while taking this drug.
  • Instruct patient to report these symptoms to physician: pain in groin or calves; sharp chest pain or sudden shortness of breath; abnormal vaginal bleeding; breast lumps; sudden severe headache; dizziness or fainting; vision or speech problems; weakness or numbness of arms or legs; severe abdominal pain; yellowing of skin or eyes; or severe depression.
  • Advise patient to stop smoking or to reduce number of cigarettes smoked to < 15/day because of increased risk of cardiovascular complications.
  • Remind patient to have Pap smear every 6–12 mo while undergoing therapy.
  • Teach patient proper method of breast self-examination.
  • Advise patient to avoid prolonged exposure to sunlight or other sources of UV light. Sunscreens and protective clothing should be used until tolerance is determined.

Popularity: 2% [?]


If you're still unable to find appropriate information in the article, please use search form below